BiotechTube

NNC0487-0111 + Placebo (matched to NNC0487-0111 )

Phase 3Recruiting
0 views this week 0 watching⚡ Active💉Featured in GLP-1 & Metabolic Watch
Interest: 47/100
47
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Obesity

Conditions

Obesity, Knee Osteoarthritis (OA)

Trial Timeline

Apr 13, 2026 → Jul 17, 2028

NCT ID
NCT07481630

About NNC0487-0111 + Placebo (matched to NNC0487-0111 )

NNC0487-0111 + Placebo (matched to NNC0487-0111 ) is a phase 3 stage product being developed by Novo Nordisk for Obesity. The current trial status is recruiting. This product is registered under clinical trial identifier NCT07481630. Target conditions include Obesity, Knee Osteoarthritis (OA).

What happened to similar drugs?

20 of 20 similar drugs in Obesity were approved

Approved (20) Terminated (5) Active (0)
✅exenatide + PlaceboEli LillyApproved
✅TirzepatideEli LillyApproved
✅Micafungin + MicafunginAstellas PharmaApproved
✅MicafunginAstellas PharmaApproved
✅Zonegran + PlaceboEisaiApproved
✅lorcaserin hydrochloride XR + PlaceboEisaiApproved
✅Placebo + TirzepatideEli LillyApproved

Hype Score Breakdown

Clinical
17
Activity
15
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT07481630Phase 3Recruiting

Competing Products

20 competing products in Obesity

See all competitors
ProductCompanyStageHype Score
MK0493MerckPhase 2
35
MK0557MerckPhase 3
40
AMG 786AmgenPhase 1
29
Bimagrumab + Tirzepatide + Bimagrumab Placebo + Tirzepatide PlaceboEli LillyPhase 2
39
TirzepatideEli LillyPhase 2
42
exenatide + PlaceboEli LillyApproved
43
BrenipatideEli LillyPhase 1
36
Orforglipron + PlaceboEli LillyPhase 3
47
TERN-601Terns PharmaceuticalsPhase 2
32
MBX 4291 + PlaceboMBX BiosciencesPhase 1
30
PG-102Rani TherapeuticsPhase 1
26
Orforglipron + PlaceboEli LillyPhase 1
29
Tirzepatide + PlaceboEli LillyPhase 3
40
Eloralintide + PlaceboEli LillyPhase 1
29
Oral Azelaprag (BGE-105) + Oral Placebo for Azelaprag (BGE-105) + Tirzepatide + Tirzepatide PlaceboEli LillyPhase 2
27
LY3437943 + Midazolam + Warfarin + CaffeineEli LillyPhase 1
29
Nimacimab injection + Nimacimab placebo injection + Nimacimab 300 mg injectionSkye BiosciencePhase 2
29
TirzepatideEli LillyApproved
50
Adenosine + RegadenosonAstellas PharmaPre-clinical
26
Micafungin + MicafunginAstellas PharmaApproved
43